Close Menu

NEW YORK – Abbott said today that it has received US Food and Drug Administration approval for use of its Alinity s System to conduct screening in US blood and plasma centers.

The system, which runs up to 600 tests per hour, has been designed to screen efficiently and within a small space, Abbott said. It added that its automation and flexibility will help blood and plasma centers improve productivity and maintain accuracy within a testing specialty that can require extensive hands-on time.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.